KR100872215B1 - 신규 올리고사카라이드를 함유하는 약학 조성물 - Google Patents

신규 올리고사카라이드를 함유하는 약학 조성물 Download PDF

Info

Publication number
KR100872215B1
KR100872215B1 KR1020077018523A KR20077018523A KR100872215B1 KR 100872215 B1 KR100872215 B1 KR 100872215B1 KR 1020077018523 A KR1020077018523 A KR 1020077018523A KR 20077018523 A KR20077018523 A KR 20077018523A KR 100872215 B1 KR100872215 B1 KR 100872215B1
Authority
KR
South Korea
Prior art keywords
formula
oligosaccharides
sodium
mixture
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020077018523A
Other languages
English (en)
Korean (ko)
Other versions
KR20070087263A (ko
Inventor
피에르 무리에
엘리사벳 페렝
크리스티앙 비스코프
장-마리 슈투쯔만
플로랑스 발
Original Assignee
아방티 파르마 소시에테 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아방티 파르마 소시에테 아노님 filed Critical 아방티 파르마 소시에테 아노님
Publication of KR20070087263A publication Critical patent/KR20070087263A/ko
Application granted granted Critical
Publication of KR100872215B1 publication Critical patent/KR100872215B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
KR1020077018523A 1999-10-22 2000-10-18 신규 올리고사카라이드를 함유하는 약학 조성물 Expired - Fee Related KR100872215B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9913182A FR2800074B1 (fr) 1999-10-22 1999-10-22 Nouveaux oligosaccharides, leur preparation et les compositions pharmaceutiques les contenant
FR99/13182 1999-10-22

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020027005061A Division KR100778166B1 (ko) 1999-10-22 2000-10-18 신규 올리고사카라이드, 이의 제조방법 및 이를 함유하는약학 조성물

Publications (2)

Publication Number Publication Date
KR20070087263A KR20070087263A (ko) 2007-08-27
KR100872215B1 true KR100872215B1 (ko) 2008-12-05

Family

ID=9551218

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020027005061A Expired - Fee Related KR100778166B1 (ko) 1999-10-22 2000-10-18 신규 올리고사카라이드, 이의 제조방법 및 이를 함유하는약학 조성물
KR1020077018523A Expired - Fee Related KR100872215B1 (ko) 1999-10-22 2000-10-18 신규 올리고사카라이드를 함유하는 약학 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020027005061A Expired - Fee Related KR100778166B1 (ko) 1999-10-22 2000-10-18 신규 올리고사카라이드, 이의 제조방법 및 이를 함유하는약학 조성물

Country Status (30)

Country Link
EP (1) EP1226148B1 (enExample)
JP (1) JP4733329B2 (enExample)
KR (2) KR100778166B1 (enExample)
CN (1) CN1241932C (enExample)
AT (1) ATE534656T1 (enExample)
AU (1) AU781414B2 (enExample)
BR (1) BR0014939A (enExample)
CA (1) CA2388369C (enExample)
CY (1) CY1112274T1 (enExample)
CZ (1) CZ303255B6 (enExample)
DK (1) DK1226148T3 (enExample)
EA (1) EA004046B1 (enExample)
EE (1) EE05091B1 (enExample)
ES (1) ES2376409T3 (enExample)
FR (1) FR2800074B1 (enExample)
HR (1) HRP20020330A2 (enExample)
HU (1) HU229385B1 (enExample)
IL (2) IL149154A0 (enExample)
ME (1) MEP9309A (enExample)
MX (1) MXPA02003945A (enExample)
NO (1) NO323409B1 (enExample)
NZ (1) NZ518539A (enExample)
PL (1) PL204623B1 (enExample)
PT (1) PT1226148E (enExample)
RS (1) RS50829B (enExample)
SK (1) SK287459B6 (enExample)
TR (1) TR200201102T2 (enExample)
UA (1) UA72545C2 (enExample)
WO (1) WO2001029055A2 (enExample)
ZA (1) ZA200203102B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4676048B2 (ja) * 2000-07-10 2011-04-27 生化学工業株式会社 脱髄性疾患処置剤
CA2431709A1 (en) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Use of low molecular heparin for treating osteoarthritis
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7575886B2 (en) 2002-03-11 2009-08-18 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
FR2844808B1 (fr) * 2002-09-23 2005-02-25 Aventis Pharma Sa Methode de determination de groupements specifiques constituant les heparines ou les heparines de bas poids moleculaire
US20040171819A1 (en) 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
US7511026B2 (en) 2003-03-25 2009-03-31 Seikagaku Corporation Therapeutic agent for nerve damage
US7956046B2 (en) * 2003-07-24 2011-06-07 Aventis Pharma S.A. Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
FR2857971B1 (fr) * 2003-07-24 2005-08-26 Aventis Pharma Sa Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
US20050186679A1 (en) * 2004-02-24 2005-08-25 Christian Viskov Method for determining specific groups constituting heparins or low molecular weight heparins
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
EP1580197A1 (en) * 2004-03-24 2005-09-28 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular wieght heparins using HPLC
DE102005017799A1 (de) * 2005-04-18 2006-10-19 Abbott Gmbh & Co. Kg Verwendung von Heparin und Heparinderivaten zur Modulation des Neuritenwachstum-kontrollierenden Nogo-Rezeptors
US8101733B1 (en) 2006-06-27 2012-01-24 Momenta Pharmaceuticals, Inc. Methods of evaluating mixtures of polysaccharides
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
EP2256138A1 (en) * 2009-05-05 2010-12-01 Sanofi-Aventis Novel acylated 1,6-anhhydro decasaccharide and its use as antithrombotic agent
FR2949114B1 (fr) * 2009-08-14 2011-08-26 Sanofi Aventis OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2949115B1 (fr) 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
ES2817779T3 (es) 2010-01-19 2021-04-08 Momenta Pharmaceuticals Inc Evaluación de preparaciones de heparina
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
CN102864191A (zh) * 2011-12-16 2013-01-09 深圳市海普瑞药业股份有限公司 肝素双糖混合物及其制备方法和应用
CN104910217B (zh) * 2015-06-19 2018-04-17 天津红日药业股份有限公司 用于磺达肝癸钠质量控制的参比化合物
CZ308106B6 (cs) * 2016-06-27 2020-01-08 Contipro A.S. Nenasycené deriváty polysacharidů, způsob jejich přípravy a jejich použití
CN110092848A (zh) * 2019-05-14 2019-08-06 山东辰龙药业有限公司 一种贝米肝素钠的制备方法
CN119708089A (zh) * 2023-09-27 2025-03-28 南开大学 一种磺酸化三糖及其制备方法和治疗应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084999A1 (fr) * 1982-01-15 1983-08-03 D.R.O.P.I.C. (Société Civile) Procédé de synthèse organique d'oligosaccharides, correspondant à des fragments de muco-polysaccharides naturels, nouveaux oligosaccharides obtenus et leurs applications biologiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2519987A1 (fr) * 1982-01-15 1983-07-22 Choay Sa Trisaccharides a structures d-glucosamine, acide d-glucuronique, d-glucosamine et leur preparation
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
JP4166851B2 (ja) * 1997-09-29 2008-10-15 生化学工業株式会社 新規虚血・再灌流障害抑制剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0084999A1 (fr) * 1982-01-15 1983-08-03 D.R.O.P.I.C. (Société Civile) Procédé de synthèse organique d'oligosaccharides, correspondant à des fragments de muco-polysaccharides naturels, nouveaux oligosaccharides obtenus et leurs applications biologiques

Also Published As

Publication number Publication date
WO2001029055A3 (fr) 2002-02-14
MXPA02003945A (es) 2002-10-23
EA200200479A1 (ru) 2002-10-31
TR200201102T2 (tr) 2002-12-23
PL363052A1 (en) 2004-11-15
PL204623B1 (pl) 2010-01-29
SK287459B6 (sk) 2010-10-07
HRP20020330B1 (enExample) 2013-01-31
YU29802A (sh) 2006-01-16
CY1112274T1 (el) 2015-12-09
KR20020063881A (ko) 2002-08-05
NO323409B1 (no) 2007-04-30
DK1226148T3 (da) 2012-03-19
KR100778166B1 (ko) 2007-11-27
IL149154A0 (en) 2002-11-10
EE200200208A (et) 2003-06-16
PT1226148E (pt) 2012-01-24
CZ303255B6 (cs) 2012-06-27
CZ20021385A3 (cs) 2002-07-17
ATE534656T1 (de) 2011-12-15
EP1226148A2 (fr) 2002-07-31
KR20070087263A (ko) 2007-08-27
AU7930200A (en) 2001-04-30
SK5272002A3 (en) 2002-08-06
HUP0203821A2 (hu) 2003-04-28
EA004046B1 (ru) 2003-12-25
IL149154A (en) 2008-04-13
EP1226148B1 (fr) 2011-11-23
NO20021859L (no) 2002-06-13
CA2388369C (fr) 2011-02-01
CA2388369A1 (fr) 2001-04-26
JP2003512385A (ja) 2003-04-02
FR2800074A1 (fr) 2001-04-27
HK1050535A1 (en) 2003-06-27
NZ518539A (en) 2004-10-29
HU229385B1 (en) 2013-11-28
HRP20020330A2 (en) 2004-04-30
FR2800074B1 (fr) 2001-12-21
NO20021859D0 (no) 2002-04-19
ES2376409T3 (es) 2012-03-13
CN1241932C (zh) 2006-02-15
HUP0203821A3 (en) 2003-10-28
CN1379781A (zh) 2002-11-13
WO2001029055A2 (fr) 2001-04-26
AU781414B2 (en) 2005-05-19
UA72545C2 (uk) 2005-03-15
ZA200203102B (en) 2003-09-23
MEP9309A (en) 2011-12-20
EE05091B1 (et) 2008-10-15
RS50829B (sr) 2010-08-31
BR0014939A (pt) 2002-06-18
JP4733329B2 (ja) 2011-07-27

Similar Documents

Publication Publication Date Title
KR100872215B1 (ko) 신규 올리고사카라이드를 함유하는 약학 조성물
US6617316B1 (en) Oligosaccharides, their preparation and pharmaceutical compositions containing them
HUP0203021A2 (hu) Eljárás reakciókésleltetett poliuretán-keményhabanyagok előállítására
DE69900718T2 (de) Synthetische polysaccharide, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
US6608042B2 (en) Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
AU782713B2 (en) Pharmaceutical compositions containing oligosaccharides and preparation thereof
HK1056564B (en) Pharmaceutical compositions containing oligosaccharides and preparation thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20121031

Year of fee payment: 5

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

FPAY Annual fee payment

Payment date: 20131101

Year of fee payment: 6

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Not in force date: 20141129

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20141129

St.27 status event code: N-4-6-H10-H13-oth-PC1903

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000